Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 7 August 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Because cumulative consolidated results for the first 3 quarters have been progressing ahead of the previous forecasts. Disclosure of a specific forecast for net income attributable to owners of the parent is being withheld because one-off gains or losses may arise from a review of the business portfolio and other factors, while fluctuations in corporate taxes and non-controlling interests are also significant, making a reasonable calculation difficult.
Impairment loss on investment securities: ¥0 million. In the same period of the previous year, ¥264 million in business structure improvement expenses was recorded.
| Item | Details |
|---|---|
| Net Sales | ¥53,000 million → ¥53,000 million |
| Operating profit | ¥3,200 million → ¥3,400 million（+6.3%） |
| Ordinary income | ¥2,800 million → ¥3,000 million（+7.1%） |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 7 August 2026 |
| Previous-period results | Revenue: ¥50,370 million; adjusted EBITDA: ¥6,938 million; operating income: ¥3,123 million; ordinary income: ¥2,365 million; net loss attributable to owners of the parent: ¥805 million. |
| Reason for the revision | Because cumulative consolidated results for the first 3 quarters have been progressing ahead of the previous forecasts. Disclosure of a specific forecast for net income attributable to owners of the parent is being withheld because one-off gains or losses may arise from a review of the business portfolio and other factors, while fluctuations in corporate taxes and non-controlling interests are also significant, making a reasonable calculation difficult. |
| Details and amount of extraordinary loss | Impairment loss on investment securities: ¥0 million. In the same period of the previous year, ¥264 million in business structure improvement expenses was recorded. |
| Dividend forecast revision | No change (whether the dividend forecast has been revised from the most recently announced forecast: No) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because cumulative results for the first 3 quarters have been progressing ahead of the previous forecasts. The factors cited include organic growth in the healthcare business, expanded sales in the biofuels business, steady performance in direct sales and distribution, and increased orders for the Satisfy Pharmaceutical Group.